First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force for some lung adenocarcinomas. Several randomized phase III studies have revealed that treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) results in an improved progression-fre...

Full description

Bibliographic Details
Main Authors: Masayuki Takeda, Kazuhiko Nakagawa
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:International Journal of Molecular Sciences
Subjects:
epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI)
mutation
non–small cell lung cancer (NSCLC)
drug resistance
Online Access:http://www.mdpi.com/1422-0067/20/1/146

Internet

http://www.mdpi.com/1422-0067/20/1/146

Similar Items